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5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used
for treatment of a variety of metastatic neoplasms including breast, gastrointestinal tract, and head and neck. 5-FU acts primarily as a thymidylate synthase inhibitor, resulting in interruption of DNA synthesis that leads to apoptotic cell death. 7 5-FU causes alimentary tract mucositis, which is characterized by a pronounced epithelial proinflammatory cytokine response and mucosal neutrophil transmigration, while the number of peripheral blood neutrophils gradually declines due to myelosuppression. 8, 9 It has been proposed that such chemotherapy agents disrupt the oral mucosal barrier, thereby promoting local invasion and systemic dissemination of commensal microorganisms; however, to our knowledge this has not been experimentally tested. Indeed, up to 50% of cases of septicemia in cancer chemotherapy patients are associated with oral microorganisms. 10 Oral viridans streptococci are responsible for up to 39% of bacteremia cases in high-dose chemotherapytreated patients, with two streptococcal species of the mitis group (Streptococcus oralis and Streptococcus mitis) most frequently isolated from blood cultures. 10, 11 In this patient population oral thrush and/ or candidemia with disseminated multi-organ infection are also prevalent and most frequently attributed to Candida albicans and Candida glabrata, two core components of the human oral mycobiota. [12] [13] [14] A recent report identified high levels of phospholipase production by C. albicans oral isolates from chemotherapy-treated cancer patients, and it was proposed that this virulence factor may elevate the risk of oral and/or systemic infection. 15 In addition, although this remains controversial, commensal microorganisms have been proposed to contribute to the initiation or persistence of mucositis. 16, 17 In a gastrointestinal mucositis germ-free mouse model it was shown that the indigenous microbiota are required for chemotherapy-induced mucosal damage. 17 However, the role of commensal organisms has never been examined in animal or in vitro models of oral mucositis.
Oral mucosal injury caused by high-dose cancer therapies can therefore result in substantial adverse impact on the clinical course of oncology patients as well as on health resource utilization. 4, 18 Despite this impact, the mechanisms involved in the pathobiology of oropharyngeal mucositis are poorly understood. New research models of chemotherapy-induced mucositis in which the role of microorganisms in pathogenesis can be fully characterized are currently needed. In this context, the aims of this study were to: a) develop an organotypic model that recapitulates the mucosal histopathologic changes that occur in oral mucositis; b) test the hypothesis that mucositis promotes biofilm formation by opportunistic fungal pathogens or commensal mitis group streptococci; and c) test the hypothesis that 5-FU treatment modifies the mucosal inflammatory responses to these organisms.
| MATERIALSANDMETHODS

| Organotypicconstructs
The oral mucosal tissue analog has been described in detail elsewhere. 19 Briefly, organotypic cultures are grown on transwell inserts that allow limited diffusion of culture media from the bottom of the 
| 5-FUtreatmentoforganotypicconstructs
In preliminary experiments the effect of 5-FU dose and duration was tested in cell proliferation assays using monolayer SCC15 cultures.
Briefly, cells were seeded at 2. 
| Evaluationofepithelialcellproliferation, apoptosisandcytotoxicity
In preliminary experiments the effect of 5-FU on cell proliferation was assessed in monolayer SCC15 cultures by labeling cells during the last 2 h of 5-FU exposure with BrdU, a synthetic analog of thymidine.
BrdU incorporation was measured using a colorimetric immunoassay kit, according to the manufacturer's instructions (Sigma-Aldrich early apoptosis marker, as previously described. 21 Briefly, tissue sections were subjected to heat-mediated antigen retrieval (10 mm citric acid and 0.05% Tween 20, pH 6.0), followed by blocking with 5% 
| EvaluationofE-cadherininepithelialjunctions
To evaluate the integrity of the mucosal barrier after exposure of organotypic constructs to 5-FU, E-cadherin was assessed by immunofluorescence staining, as described previously. 8 Briefly, paraffinembedded tissue sections were stained using an anti-E-Cadherin polyclonal antibody (BD Biosciences, San Jose, CA) followed by a fluorescein isothiocyanate-conjugated secondary antibody (DyLight 
| Evaluationofleukocytetrans-epithelial migrationinmucosalconstructs
To test whether 5-FU treatment facilitates neutrophil transmigra- 
| Microorganismsandinfection
Candida albicans strain SN425 (reference strain, derived from SC5314) has a normal hyphal phenotype and was provided by Dr. Clarissa J.
Nobile (University of California, Merced, CA). Candida glabrata strain GDH2269 is a human oral commensal isolate obtained from ATCC.
Candida strains were maintained in YPD agar (1% yeast extract, 2%
peptone, 2% dextrose, 2% agar; Fisher Scientific, Pittsburgh, PA) and and fungal metabolic activity was measured using the XTT assay, as previously described.
23
Streptococcus oralis 34 (kindly provided by Dr. P. Kolenbrander) and S. mitis 49456 (ATCC) were grown in brain-heart infusion medium (Oxoid, Thermo Scientific, Waltham, MA), under aerobic static conditions at 37°C, in a 5% CO 2 incubator, 1 day before each experiment.
Before each experiment overnight stationary phase cultures of streptococci were inoculated in fresh brain-heart infusion broth and then allowed to reach the late logarithmic phase for 3-4 h (optical density at 600 nm of 1.0, corresponding to 10 7 cells mL Mucosal biofilm formation was assessed in 5 μm thick, paraformaldehyde-fixed, paraffin-embedded tissue sections as we previously described. 20, 21, 27 Briefly, sections were stained by immunofluorescence for C. albicans or C. glabrata with a fluorescein isothiocyanate-labeled anti-Candida polyclonal antibody (Meridian Life Science, Saco, ME). For S. oralis and S. mitis biofilms, fluorescence in situ hybridization with the Streptococcus-specific oligonucleotide probe STR405 was used as described previously. 21 Tissues infected with C. albicans were counterstained for E-cadherin, as we have previously shown E-cadherin dissolution to be associated with greater mucosal invasion of this organism. 28, 29 In these tissues E-cadherin was visualized using Alexa 568-conjugated secondary antibody (1:100 dilution, A11031; Invitrogen). Biofilms were quantified on each mucosal construct using Image J to measure the area occupied by microorganisms both above and below the epithelial layer in four to eight microscopic fields per tissue sample. Images were obtained using a Zeiss
Axio Imager M1 microscope and an EC Plan-Neofluar 20× NA 0.5 air objective and further analyzed using the AXIOVISION LE64 software.
| Assessmentofcytokines
Cytokine production was assessed in organotypic culture-conditioned media after 16 h of 5-FU exposure. In infection experiments, cytokines were quantified after 16 h of biofilm growth on tissues that had been exposed to 5-FU (10 μm) for 16 h before microbial inoculation, as described above. Tissue-conditioned media from 5-FU-untreated cultures inoculated with microorganisms for 16 h served as controls in these experiments. Before cytokine assays, total protein concentration was quantified in each sample using a BCA protein assay kit (Thermo Fisher Scientific). Samples were diluted as needed so as to standardize the amount of protein analyzed for cytokine content, since the total epithelial cell numbers corresponding to each sample varies due to the fact that each organotypic culture has a slightly variable number of epithelial cell layers. Granulocyte-macrophage colonystimulating factor (GM-CSF), interleukin 1β (IL-1β), IL-6, IL-8, IL-10 and tumor necrosis factor-α (TNF-α) were simultaneously quantified in each sample using the Luminex/MAGPIX system (HSTCMAG-28SK; Millipore, Billerica, MA).
| Statisticalanalyses
Data were analyzed using one-way analysis of variance or the KruskalWallis test, when data did not pass the normality test. Analyses were performed using the graph-pad prIsm ® software. Statistical significance for all tests was set at P < .05.
| RESULTS
| 5-FUinhibitsepithelialcellproliferationina time-anddose-dependentmanner
We first used monolayer epithelial cultures to establish a dose range and duration of 5-FU treatment that inhibit cell proliferation without completely compromising cell culture viability ( Figure S1A ). Cell 
| 5-FU-treatedorganotypicconstructsexhibit histopathologiccharacteristicsoforalmucositis
We next examined the effect of 5-FU treatment in organotypic oral mucosal constructs. Based on our preliminary observations above, lower concentrations of 5-FU (1-10 μm) were used with the intent to minimize toxicity and preserve the three-dimensional organization and structure of tissue constructs after treatment. A histologic examination of 5-FU-treated constructs using a hematoxylin & eosin stain revealed no significant structural alterations on the multi-layer epithelium ( Figure 1A) . However, at the higher dose tested (10 μm), more widening of epithelial intercellular spaces and cytoplasmic vacuolation were noted, consistent with histopathologic characteristics of oral mucositis. 30 These changes were accompanied by a statistically significant increase in LDH release compared with tissues treated with 1 μm 5-FU, which triggered similar LDH release levels with untreated tissues ( Figure 1B) . Figure S2 ). As these layers were closer to the basally supplied media, it is reasonable to assume that they were exposed to the drug earlier, so undergoing late-stage apoptotic changes. Collectively, these results
showed that treatment of organotypic constructs for 16 h with lower concentrations of 5-FU reproduced the major histopathologic characteristics of oral mucositis in vivo. 
| 5-FUtreatmentdoesnotsignificantlyalter mucosalbiofilmgrowth
To test the hypothesis that mucosal damage inflicted by 5-FU promotes microbial growth, we exposed tissues to 5-FU for 16 h and then inoculated them with microorganisms for an additional 16 h incubation period. Preliminary experiments showed that 5-FU concentrations ranging between 0.08 and 8 μm inhibited fungal biofilm metabolic activity ( Figure S3 ), so before microbial inoculation 5-FU was removed from tissue constructs and fresh culture media were added basolaterally, as described in the Materials and methods. The biofilm surface area on 5-FU-treated mucosal constructs formed by
C. glabrata, S. oralis and S. mitis increased by approximately two-fold
compared with untreated constructs, however, with the exception of S. oralis, this increase was not statistically significant ( Figure 5A ).
In some 5-FU-treated tissues infected with C. albicans, areas of localized mucosal fungal invasion, corresponding to reduced E-cadherin signal, were observed in 6-h biofilms (arrows, Figure 5B ). However, after 16 h of growth, extensive tissue damage with hyphal organisms traversing through the entire submucosal compartment were noted, in both 5-FU-treated and untreated tissues (arrows, Figure 5B ). Along the same lines, in C. glabrata biofilms, organisms could be seen frequently as clusters within epithelial layers in 5-FU-treated constructs (arrows, Figure 5C ). Finally, both streptococcal species formed superficial, non-invasive biofilms regardless of 5-FU tissue treatment ( Figure 5C ).
| 5-FU-treatedorganotypicconstructs respondtocommensalorganismswithincreased proinflammatorycytokines
To (Table 1) .
We next tested the hypothesis that 5-FU treatment affects the epithelial proinflammatory response to microbial challenge by comparing 5-FU-treated and untreated mucosal tissues in their cytokine response to mucosal biofilm growth. As expected from our previous work in organotypic models 32, 33 in untreated tissues, C. albicans elicited a release of all proinflammatory cytokines tested, which was significantly higher compared with C. glabrata and S. oralis. In general, the cytokine response of untreated tissues to C. glabrata or S. oralis biofilms was low and close to control (uninfected) tissue levels ( Table 1 and Figure 6 ). Importantly, C. albicans induced a significantly higher production of GM-CSF and TNF-α in 5-FU-treated compared with untreated tissues. Similarly, 5-FU-treated tissues responded to C. glabrata with a higher IL-6 response, compared with untreated tissues (Figure 6 ). Along the same lines, S. oralis triggered a significant IL-6 release above uninfected levels only in 5-FU-treated tissues (Table 1 and Figure 6 ). In summary, these results suggest that 5-FU treatment primes the oral mucosa for an exacerbated proinflammatory response to certain fungal and bacterial commensal organisms.
| DISCUSSION
Three-dimensional organotypic constructs provide an organizational complexity that is between the culture of single cell types and ex vivo organ cultures. In this setting epithelial cells form multiple stratified layers resembling the upper alimentary tract mucosa both morphologically and functionally. 19 Using an oral mucosal organotypic con- hTERT-immortalized oral epithelial cells. 19, 22 Several models were recently developed where the effects of either ionizing radiation or a chemotherapy agent (everolimus) on oral keratinocyte proliferation and inflammatory cytokine responses were examined, to recapitulate the mucositis-associated epithelial changes observed in vivo. [36] [37] [38] [39] Most of these models used commercially available organotypic constructs and were characterized by a modest IL-6 and IL-8, but no detectable TNF-α, epithelial response. [36] [37] [38] By comparison, in our model in addition to TNF-α, 5-FU induced a GM-CSF, IL-6 and IL-8 response in oral epithelium, which resembles the inflammatory response of the oral mucosa in humans 1 and animals. ). 40 Interestingly, the optimal concentration of 5-FU in our organotypic model was similar to the effective initial blood concentration of 5-FU in a mouse model of oral mucositis. 8 In this recently published animal model, 5-FU chemotherapy reduced E-cadherin in oral and esophageal mucosal tissues. Oral microbial community shifts during chemotherapy or radiotherapy have been studied in multiple cancer patient studies, with no emerging consistent patterns of change with mucositis development. 16, 42, 43 In this study we tested the hypothesis that mucosal fungal or bacterial biofilm growth may be more robust on tissues treated Results represent mean cytokine levels of the two conditions tested in triplicate in two independent experiments *P < .05, **P < .01.
media, promotes growth of fastidious streptococci when added to a chemically defined bacterial growth medium. 46 This may explain the small but perhaps biologically significant increase in S. oralis and S. mitis biofilms in 5-FU-treated tissues. However, there was no detectable significant increase in fungal biofilm growth on 5-FU-treated mucosal surfaces, suggesting that epithelial damage alone may not be sufficient in promoting overgrowth of fungi on mucositis-affected tissues.
As the oral microbiota is in constant cross-talk with the oral mucosa, it is plausible that microbial challenge of mucosal cells may contribute to inflammatory events that aggravate oral mucositis.
Although very few studies have analyzed the relationship between mucositis severity and changes in the fungal and bacterial microbiome longitudinally in humans, a recent study 16 showed that as muco- 
